In the present project, WES was performed at the BEA core facility, KI on Glioblastoma (GB) patient tumor samples (n=9), and matched peripheral monocytes (CD14+) as germline reference (9). In additon, WES on primary human GBM cell cultures (n=3), established human GBM cell-lines (n=2), and established mouse GBM cell-line (n=1). In total, 24 WES samples. Also, RNA seq. was performed on human patient GBM samples (n=9), human GBM cell cultures (n=3, triplicates), and established mouse GBM cell-line (n=1, triplicates). In total, 21 RNA seq. samples. The aim is to identify somatic nonsynonymous mutations. We will then correlate WES and RNA seq. data with already identified peptides from LC-MS/MS of matched tumor tissue. Of specific interest are mutations residing in extracellular proteins and in extracellular domain of cell-surface proteins as putative targets for immunotherapy.